PURPOSE：Toevaluatethetoxicityandresponserateofbortezomibwithconcurrentradiotherapyandtemozolomideinthetreatmentofpatientswithcentralnervoussystemmalignancies.PATIENTSANDMETHODS：Thisopen-label,dose-escalation,PhaseⅠclinicalstudyevaluatedthesafetyofthreedoselevelsofintravenouslyadministeredbortezomib（0.7,1.0,and1.3mg/m（2）/dose）onDays1,4,8,and11ofa21-daycycle,inadditiontoconcurrentradiotherapyandtemozolomideatadailydoseof75mg/m（2）startingonDay1.Theprimaryendpointwasdose-limitingtoxicity,definedasanyGrade4-5toxicityorGrade3toxicitydirectlyat-tr/butabletoprotocoltreatment,requiringhospitalizationand/orradiotherapyinterruption.
